Prevalence of Helicobacter pylori antibodies in long-term dialysis patients.
BACKGROUND
Helicobacter pylori has been reported to play an important role in the development of gastritis and gastric ulcer.


METHODS
This study included 168 patients with end-stage renal disease (ESRD; 30 non-dialysis patients, 138 patients receiving dialysis; mean duration of dialysis: 57.3 +/- 61.7 months) and 138 control volunteers. We investigated the prevalence of H. pylori infection by measuring H. pylori antibody (IgG) levels.


RESULTS
The prevalence of H. pylori infection was 62.3% in the control group, 53.3% in the non-dialysis patients, and 36.9% in the dialysis patients. The percentage decreased with a reduction of renal function. In addition, the proportion of H. pylori-positive patients decreased with the duration of dialysis, and the antibody titre was also significantly decreased. There was no association between long-term oral administration of H2RA (H2 receptor antagonist) and the incidence of H. pylori infection.


CONCLUSIONS
Among dialysis patients, the proportion of H. pylori-positive patients was low. An aetiological factor other than H2RA agents was suggested. Renal failure or dialysis treatment may influence H. pylori infection.
Nakajima
Fumitaka
F
Department of Nephrology, Moriguchi Keijinkai Hospital, Moriguchi, Japan. fumitaka@mti.biglobe.ne.jp
Sakaguchi
Masahiro
M
Oka
Hiroshi
H
Kawase
Yoshio
Y
Shibahara
Nobuhisa
N
Inoue
Toru
T
Ueda
Haruhiko
H
Katsuoka
Yoji
Y
D000328:Adult; D000367:Age Factors; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D005260:Female; D016480:Helicobacter pylori / Q000276:immunology*; D006635:Histamine H2 Antagonists / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D013997:Time Factors
D000907:Antibodies, Bacterial; D006635:Histamine H2 Antagonists